Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 194

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

KRAS Mutation in Stage III Colon Cancer and Clinical Outcome Following Intergroup Trial CALGB 89803

Open access
Ogino, Shuji, Meyerhardt, Jeffrey A., Irahara, Natsumi, Niedzwiecki, Donna, Hollis, Donna, Saltz, Leonard B., Mayer, Robert J., Schaefer, Paul, Whittom, Renaud, Hantel, Alexander, Benson, Al B., Goldberg, Richard M., Bertagnolli, Monica M., Fuchs, Charles S., for the Cancer and Leukemia Group B, North Central Cancer Treatment Group, Canadian Cancer Society Research Institute, Southwest Oncology Group · 2009 · Clinical Cancer Research

Abstract

Purpose: Alterations in the RAS and RAF pathway relate to epigenetic and epigenomic aberrations, and are important in colorectal carcinogenesis. KRAS mutation in metastatic colorectal cancer predicts resistance to anti–epidermal growth factor receptor (EGFR)-targeted therapy (cetuximab or panitumumab). It remains uncertain, however, whether KRAS mutation predicts prognosis or clinical outcome of colon cancer patients independent of anti-EGFR therapy. Methods: We conducted a study of 508 cases identified among 1,264 patients with stage III colon cancer who enrolled in a randomized adjuvant chemotherapy trial (5-fluorouracil, leucovorin with or without irinotecan) in 1999-2001 (CALGB 89803). KRAS mutations were detected in 178 tumors (35%) by pyrosequencing. Kaplan-Meier and Cox proportional hazard models assessed the prognostic significance of KRAS mutation and adjusted for potential confounders including age, sex, tumor location, tumor/node stage, performance status, adjuvant chemotherapy arm, and microsatellite instability status. Results: Compared with patients with KRAS-wild-type tumors, patients with KRAS-mutated tumors did not experience any difference in disease-free, recurrence-free, or overall survival. The 5-year disease-free, recurrence-free, and overall survival rates (KRAS-mutated versus KRAS-wild-type patients) were 62% versus 63% (log-rank P = 0.89), 64% versus 66% (P = 0.84), and 75% versus 73% (P = 0.56), respectively. The effect of KRAS mutation on patient survival did not significantly differ according to clinical features, chemotherapy arm, or microsatellite instability status, and the effect of adjuvant chemotherapy assignment on outcome did not differ according to KRAS status. Conclusions: In this large trial of chemotherapy in stage III colon cancer patients, KRAS mutational status was not associated with any significant influence on disease-free or overall survival. (Clin Cancer Res 2009;15(23):7322–9)

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-09-1570

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 40

  1. Jimeno, 2009, KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection, J Clin Oncol, 27, 1130, 10.1200/JCO.2008.19.8168 · DOI · Paper page
  2. Riely, 2008, KRAS mutations: an old oncogene becomes a new predictive biomarker, J Mol Diagn, 10, 493, 10.2353/jmoldx.2008.080105 · DOI
  3. Hamilton, 2008, Targeted therapy of cancer: new roles for pathologists in colorectal cancer, Mod Pathol, 21 Suppl 2, S23, 10.1038/modpathol.2008.14 · DOI
  4. Samowitz, 2000, Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study, Cancer Epidemiol Biomarkers Prev, 9, 1193
  5. Brink, 2003, K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study, Carcinogenesis, 24, 703, 10.1093/carcin/bgg009 · DOI · Paper page
  6. Ogino, 2009, CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer, Gut, 58, 90, 10.1136/gut.2008.155473 · DOI · Paper page
  7. Lievre, 2008, KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab, J Clin Oncol, 26, 374, 10.1200/JCO.2007.12.5906 · DOI · Paper page
  8. Lievre, 2006, KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer, Cancer Res, 66, 3992, 10.1158/0008-5472.CAN-06-0191 · DOI · Paper page
  9. De Roock, 2008, KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab, Ann Oncol, 19, 508, 10.1093/annonc/mdm496 · DOI · Paper page
  10. Freeman, 2008, Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone, Clin Colorectal Cancer, 7, 184, 10.3816/CCC.2008.n.024 · DOI · Paper page
  11. Khambata-Ford, 2007, Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab, J Clin Oncol, 25, 3230, 10.1200/JCO.2006.10.5437 · DOI · Paper page
  12. Karapetis, 2008, K-ras mutations and benefit from cetuximab in advanced colorectal cancer, N Engl J Med, 359, 1757, 10.1056/NEJMoa0804385 · DOI · Paper page
  13. Bokemeyer, 2009, Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer, J Clin Oncol, 27, 663, 10.1200/JCO.2008.20.8397 · DOI · Paper page
  14. Klump, 2004, Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature, Int J Colorectal Dis, 19, 23, 10.1007/s00384-003-0499-7 · DOI
  15. Anwar, 2004, Systematic review of genetic influences on the prognosis of colorectal cancer, Br J Surg, 91, 1275, 10.1002/bjs.4737 · DOI
  16. Westra, 2004, Genetic alterations in locally advanced stage II/III colon cancer: a search for prognostic markers, Clin Colorectal Cancer, 4, 252, 10.3816/CCC.2004.n.024 · DOI
  17. van Krieken, 2008, KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program, Virchows Arch, 453, 417, 10.1007/s00428-008-0665-y · DOI · Paper page
  18. Barault, 2008, Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases, Cancer Res, 68, 8541, 10.1158/0008-5472.CAN-08-1171 · DOI · Paper page
  19. Wang, 2003, Prognostic significance of microsatellite instability and Ki-ras mutation type in stage II colorectal cancer, Oncology, 64, 259, 10.1159/000069311 · DOI
  20. Gnanasampanthan, 2001, Ki-ras mutation type and the survival benefit from adjuvant chemotherapy in Dukes' C colorectal cancer, J Pathol, 195, 543, 10.1002/path.990 · DOI
  21. Ince, 2005, Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab, J Natl Cancer Inst, 97, 981, 10.1093/jnci/dji174 · DOI · Paper page
  22. Roth, 2009, Correlation of molecular markers in colon cancer with stage-specific prognosis: Results of the translational study on the PETACC 3 - EORTC 40993-SAKK 60–00 trial [abstract No. 288], J Clin Oncol, 10.1200/jco.2009.27.15_suppl.4002 · doi:10.1200/jco.2009.27.15_suppl.4002
  23. Saltz, 2007, Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803, J Clin Oncol, 25, 3456, 10.1200/JCO.2007.11.2144 · DOI · Paper page
  24. Zubrod, 1960, Appraisal of methods for the study of chemotherapy in man: comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide, J Chron Dis, 11, 7, 10.1016/0021-9681(60)90137-5 · DOI · Paper page
  25. Ogino, 2005, Sensitive sequencing method for KRAS mutation detection by Pyrosequencing, J Mol Diagn, 7, 413, 10.1016/S1525-1578(10)60571-5 · DOI · Paper page
  26. Bertagnolli, 2009, Microsatellite instability predicts improves response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803, J Clin Oncol, 27, 1814, 10.1200/JCO.2008.18.2071 · DOI · Paper page
  27. Nosho, 2008, Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample, PLoS ONE, 3, e3698, 10.1371/journal.pone.0003698 · DOI · Paper page
  28. Ogino, 2008, A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer, J Natl Cancer Inst, 100, 1734, 10.1093/jnci/djn359 · DOI · Paper page
  29. Ogino, 2009, PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer, J Clin Oncol, 27, 1477, 10.1200/JCO.2008.18.6544 · DOI · Paper page
  30. Velho, 2005, The prevalence of PIK3CA mutations in gastric and colon cancer, Eur J Cancer, 41, 1649, 10.1016/j.ejca.2005.04.022 · DOI · Paper page
  31. Nosho, 2008, PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations, Neoplasia, 10, 534, 10.1593/neo.08336 · DOI · Paper page
  32. Ogino, 2006, CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations, J Mol Diagn, 8, 582, 10.2353/jmoldx.2006.060082 · DOI · Paper page
  33. Shen, 2007, Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer, Proc Natl Acad Sci U S A, 104, 18654, 10.1073/pnas.0704652104 · DOI · Paper page
  34. Ogino, 2007, Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer, Gut, 56, 1409, 10.1136/gut.2007.119750 · DOI
  35. Ogino, 2008, Molecular classification and correlates in colorectal cancer, J Mol Diagn, 10, 13, 10.2353/jmoldx.2008.070082 · DOI · Paper page
  36. Ogino, 2005, Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer, Clin Cancer Res, 11, 6650, 10.1158/1078-0432.CCR-05-0738 · DOI
  37. Andreyev, 2001, Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study, Br J Cancer, 85, 692, 10.1054/bjoc.2001.1964 · DOI · Paper page
  38. Andreyev, 1998, Kirsten ras mutations in patients with colorectal cancer: the multicenter “RASCAL” study, J Natl Cancer Inst, 90, 675, 10.1093/jnci/90.9.675 · DOI · Paper page
  39. Finkelstein, 1993, Determination of tumor aggressiveness in colorectal cancer by K-ras-2 analysis, Arch Surg, 128, 526, 10.1001/archsurg.1993.01420170056008 · DOI
  40. Nemunaitis, 1997, Irinotecan hydrochloride (CPT-11) resistance identified by K-ras mutation in patients with progressive colon cancer after treatment with 5-fluorouracil (5-FU), Am J Clin Oncol, 20, 527, 10.1097/00000421-199710000-00020 · doi:10.1097/00000421-199710000-00020

Cited by

See all 194

Metadata

Authors
Ogino, S., Meyerhardt, J. A., Irahara, N., Niedzwiecki, D., Hollis, D., Saltz, L. B., Mayer, R. J., Schaefer, P., Whittom, R., Hantel, A., Benson, A. B., Goldberg, R. M., Bertagnolli, M. M., Fuchs, C. S., & for the Cancer and Leukemia Group B, N. C. C. T. G.
Venue
Clinical Cancer Research
Published
2009-11-30
Volume
15
Issue
23
Pages
7322-7329
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2104573387
Cited by
194
References
5
FWCI
9.40
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: KRAS Mutation in Stage III Colon Cancer and Clinical Outcome Following Intergroup Trial CALGB 89803. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-09-1570
The paper
Ogino, S., Meyerhardt, J. A., Irahara, N., Niedzwiecki, D., Hollis, D., Saltz, L. B., Mayer, R. J., Schaefer, P., Whittom, R., Hantel, A., Benson, A. B., Goldberg, R. M., Bertagnolli, M. M., Fuchs, C. S., & for the Cancer and Leukemia Group B, N. C. C. T. G. (2009). KRAS Mutation in Stage III Colon Cancer and Clinical Outcome Following Intergroup Trial CALGB 89803. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-09-1570

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.